CA2565182A1 - Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer - Google Patents

Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer Download PDF

Info

Publication number
CA2565182A1
CA2565182A1 CA002565182A CA2565182A CA2565182A1 CA 2565182 A1 CA2565182 A1 CA 2565182A1 CA 002565182 A CA002565182 A CA 002565182A CA 2565182 A CA2565182 A CA 2565182A CA 2565182 A1 CA2565182 A1 CA 2565182A1
Authority
CA
Canada
Prior art keywords
microspheres
tki
biodegradable
aqueous phase
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002565182A
Other languages
French (fr)
Other versions
CA2565182C (en
Inventor
Patrick M. Hughes
Christian Sarrazin
Elisabeth Rossi
Michele Boix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan, Inc.
Patrick M. Hughes
Christian Sarrazin
Elisabeth Rossi
Michele Boix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc., Patrick M. Hughes, Christian Sarrazin, Elisabeth Rossi, Michele Boix filed Critical Allergan, Inc.
Priority to CA2838526A priority Critical patent/CA2838526C/en
Publication of CA2565182A1 publication Critical patent/CA2565182A1/en
Application granted granted Critical
Publication of CA2565182C publication Critical patent/CA2565182C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Abstract

Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.

Claims (17)

1. A biodegradable intravitreal implant comprising:
a plurality of biodegradable polymer microspheres encapsulating a tyrosine kinase inhibitor (TKI), the microspheres releasmg the TKI at a rate effective to sustain release of the TKI from the microspheres for at least about one week after the implant is placed in the vitreous of an eye.
2. The implant of claim 1, wherein the polymer is selected from the group consisting of polylactides, poly (Iactide-co-glycolides), polycaprolactones, derivatives thereof, and mixtures thereof.
3. The implant of claim 1, wherein the microspheres release the TKI at a rate effective to sustain release of an amount of the TKI from the implant for more than one month from the time the implant is placed in the vitreous of the eye.
4. The implant of claim 1, wherein the tyrosine kinase inhibitor is provided in an amount from about 40% by weight to about 60% by weight of the implant, and the biodegradable polymer matrix comprises a poly (lactide-co-glycolide) in an amount from about 40% by weight to about 60% by weight of the implant.
5. A process for making biodegradable active agent microspheres, the process comprising the steps of:
(a) preparing an organic phase, which comprises, a tyrosine kinase inhibitor (TKI), a biodegradable polymer, and a solvent for the TKS and the polymer;
(b) preparing a first aqueous phase;
(c) combining the organic and the aqueous phase to form an emulsion;
(d) preparing a second aqueous phase;
(e) adding the second aqueous phase to the emulsion to form a solution (f) stirring the solution, and;
(g) evaporating the solvent, thereby making biodegradable microspheres encapsulating the TKI.
6. The process of claim 5, wherein the organic phase is a viscous fluid.
7. The process of claim 5, further comprising the step of crystallizing the TKI in the organic phase.
8. The process of claim 5, further comprising the step of crystallizing the TKI in the emulsion.
9. The process of claim 5, wherein the pH of the first aqueous phase is between about pH 6 and about pH 8.
10. The process of claim 5, wherein the pH of the second aqueous phase is between about pH 4 and about pH 9.
11. A process for making biodegradable active agent microspheres, the process comprising the steps of:
(a) preparing a viscous organic phase, which comprises, a TKI, a biodegradable PLGA polymer, and a solvent for the active agent and the PLGA polymer;
(b) crystallizing active agent in the viscous organic phase (c) preparing a first aqueous phase with a pH between about pH 6 and about pH
8;
(d) combining the organic and the aqueous phase to form an emulsion;
(e) crystallizing active agent in the emulsion;
(f) preparing a second aqueous phase with a pH between about pH 4 and about pH

9;

(g) adding the second aqueous phase to the emulsion to form a solution (h) stirring the solution, and;
(i) evaporating the solvent, thereby making biodegradable active agent microspheres.
12. Biodegradable active agent microspheres made by the process of claim 5.
13. The process of claim 11, wherein the active agent is a TKI.
14. A medicament, which comprises biodegradable intraocular microspheres, for treating an ocular condition of an eye of a patient by placing biodegradable intraocular microspheres into the vitreous of an eye of the patient, the rnicrospheres comprising a TKI and a biodegradable polymer, wherein the microspheres degrades at a rate effective to sustain release of an amount of the TIG from the microspheres effective to treat the ocular condition.
15. The medicament of claim 14, wherein the method is effective to treat a retinal ocular condition.
16. The medicament of claim 14, wherein the ocular condition is glaucoma.
17. The medicament of claim 14, wherein the ocular condition is proliferative vitreoretinopathy.
CA2565182A 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer Active CA2565182C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2838526A CA2838526C (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/837,361 US7771742B2 (en) 2004-04-30 2004-04-30 Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US10/837,361 2004-04-30
PCT/US2005/014811 WO2005112884A1 (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2838526A Division CA2838526C (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Publications (2)

Publication Number Publication Date
CA2565182A1 true CA2565182A1 (en) 2005-12-01
CA2565182C CA2565182C (en) 2014-07-08

Family

ID=34967821

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2838526A Active CA2838526C (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer
CA2565182A Active CA2565182C (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2838526A Active CA2838526C (en) 2004-04-30 2005-04-27 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer

Country Status (7)

Country Link
US (7) US7771742B2 (en)
EP (2) EP1742610B1 (en)
JP (5) JP2007535556A (en)
AU (2) AU2005244780B2 (en)
BR (1) BRPI0509461A (en)
CA (2) CA2838526C (en)
WO (2) WO2005112884A1 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
MXPA04009434A (en) * 2002-04-03 2005-01-25 Allergan Inc (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors.
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
BRPI0506983A (en) 2004-01-20 2007-07-03 Allergan Inc localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8455656B2 (en) * 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
CN101180086A (en) * 2005-04-08 2008-05-14 苏尔莫迪克斯公司 Sustained release implants for subretinal delivery
JP5192384B2 (en) 2005-09-22 2013-05-08 メディバス エルエルシー Bis- (α-amino) -diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
SMP200800060B (en) 2006-04-07 2009-07-14 Procter & Gamble Antibodies that bind the human protein tyrosine phosphatase beta (hptbeta) and their uses
JP5445130B2 (en) * 2006-05-02 2014-03-19 メディバス エルエルシー Delivery of ophthalmic drugs to the exterior or interior of the eye
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20090304576A1 (en) * 2006-08-08 2009-12-10 Warren Stephen L Device for delivery of anti-cancer agents to tissue
KR20090082447A (en) * 2006-11-09 2009-07-30 알콘 리서치, 리미티드 Water insoluble polymer matrix for drug delivery
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN105412094A (en) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
AU2011207281B2 (en) * 2010-01-22 2016-10-20 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
KR20140060274A (en) * 2011-06-10 2014-05-19 램스코르 인코포레이티드 Sustained release formulations for delivery of proteins to the eye and methods of preparing same
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103748139B (en) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
MX363351B (en) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer.
AU2013209452B2 (en) 2012-01-19 2015-11-05 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
EP2825166A1 (en) 2012-03-12 2015-01-21 Allergan, Inc. Method of treating ophthalmic conditions with kinase inhibitors
US8889870B2 (en) 2012-03-12 2014-11-18 Allergan, Inc. Kinase inhibitors
JP6138904B2 (en) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー Nonlinear multiblock copolymer drug conjugates for delivery of active agents
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166498A1 (en) 2012-05-04 2013-11-07 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2964194B1 (en) 2013-03-05 2022-08-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
US20140271772A1 (en) * 2013-03-15 2014-09-18 Barry J. Margulies Biodegradable subcutaneous implants and methods of making
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10010610B2 (en) 2014-01-16 2018-07-03 Retinal Therapies, LLC Compositions and methods for the treatment of intraocular neovascularization and/or leakage
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2016100392A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
JP6846351B2 (en) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー Hypotonic hydrogel formulation for enhanced transport of active agents on mucosal surfaces
CA2986692A1 (en) * 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
MA42953A (en) 2015-09-22 2018-08-01 Graybug Vision Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
BR112018005499A2 (en) 2015-09-23 2018-10-09 Aerpio Therapeutics Inc methods of treating intraocular pressure with tie-2 activators.
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
MX2018005932A (en) 2015-11-12 2019-05-20 Graybug Vision Inc Aggregating microparticles for therapy.
WO2017184881A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
US10751367B2 (en) 2016-05-27 2020-08-25 Corning Incorporated Bioactive glass microspheres
US10647962B2 (en) 2016-05-27 2020-05-12 Corning Incorporated Bioactive aluminoborate glasses
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
US10059621B2 (en) 2016-05-27 2018-08-28 Corning Incorporated Magnetizable glass ceramic composition and methods thereof
US10676713B2 (en) 2016-05-27 2020-06-09 Corning Incorporated Bioactive borophosphate glasses
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
RU2019102647A (en) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. PYRIMIDINE-BASED ANTIPROLIFERATING AGENTS
BR112019019452A2 (en) 2017-03-23 2020-04-14 Graybug Vision Inc compound, and, use of a compound
RU2019139817A (en) 2017-05-10 2021-06-10 Грейбуг Вижн, Инк. DELAYED RELEASE MICROPARTICLES AND THEIR SUSPENSIONS FOR DRUG THERAPY
US11253480B2 (en) 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
WO2019108571A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Chemically strengthened bioactive glass-ceramics
WO2019108557A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Bioactive borate glass and methods thereof
WO2019108558A1 (en) 2017-11-28 2019-06-06 Corning Incorporated High liquidus viscosity bioactive glass
EP3717030A1 (en) 2017-11-28 2020-10-07 Corning Incorporated Bioactive glass compositions and dentin hypersensitivity remediation
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US11883525B2 (en) 2019-05-31 2024-01-30 Dose Medical Corporation Bioerodible polyester polymer axitinib ocular implants and related methods of use
KR20220036946A (en) 2019-06-27 2022-03-23 레이어바이오 인크. Ocular Device Delivery Methods and Systems
WO2021237096A1 (en) * 2020-05-21 2021-11-25 Graybug Vision, Inc. Durable implants and microparticles for long-term ocular therapy
CN111861124B (en) * 2020-06-18 2023-07-25 汕头大学 Identifiable performance evaluation method, identifiable performance evaluation system and storage medium applicable to injection molding machine
AU2021329820A1 (en) * 2020-08-18 2023-03-09 Oakwood Laboratories, Llc Microsphere formulations comprising ketamine and methods for making and using the same
TW202228789A (en) 2020-10-15 2022-08-01 美商建南德克公司 Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (en) * 1974-02-18 1976-12-13 N G Y Torphammar RELEASE DEVICE PREFERRED FOR A SAFETY BELT IN A VEHICLE
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (en) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Aperture control circuit for TTL auto strobe
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (en) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Cooking and roasting utensils with lids provided with metal handles, in particular stainless steel handles
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4693885A (en) * 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
FR2577509B1 (en) 1985-02-21 1987-05-07 Nirvana Espar Systems Sa SAILING BOAT MAT
US4656186A (en) * 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
FR2594438B1 (en) * 1986-02-14 1990-01-26 Labaz Sanofi Nv INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING SAME
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
DE3734223A1 (en) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg IMPLANTABLE, BIODEGRADABLE ACTIVE SUBSTANCE RELEASE SYSTEM
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5190966A (en) * 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5093349A (en) * 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
ATE420857T1 (en) 1988-09-06 2009-01-15 Pfizer Health Ab PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
US5595945A (en) * 1989-01-05 1997-01-21 The United States Of America As Represented By The Department Of Energy Ceramic composite coating
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) * 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5100431A (en) * 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
KR0185215B1 (en) * 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
ATE142460T1 (en) * 1991-06-21 1996-09-15 Genetics Inst MEDICINAL PRODUCTS CONTAINING OSTEOGENIC PROTEINS
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
IT1263116B (en) 1992-04-09 1996-07-30 Rotta Research Lab BASIC DERIVATIVES OF GLUTAMIC ACID AND ASPARTIC ACID, PROCEDURE FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
US5655832A (en) * 1992-04-16 1997-08-12 Tir Technologies, Inc. Multiple wavelength light processor
US5244914A (en) * 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6217869B1 (en) * 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (en) * 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraocular lens arrangement for astigmatism correction
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6270492B1 (en) * 1994-09-09 2001-08-07 Cardiofocus, Inc. Phototherapeutic apparatus with diffusive tip assembly
US6113941A (en) 1994-09-30 2000-09-05 Takeda Chemical Industries, Ltd. Substained release microcapsule of physiologically active compound which is slightly water soluble at pH 6 to 8
JPH08151322A (en) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd Oral sustained release agent
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5906920A (en) * 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en) * 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) * 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
JP2001513369A (en) * 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド Sterile bioerodible implant devices and methods with improved biocompatibility
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6271220B1 (en) * 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
ATE365550T1 (en) * 1998-03-13 2007-07-15 Univ Johns Hopkins Med USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY
WO2000002491A1 (en) 1998-07-09 2000-01-20 Curelight Ltd. Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea
US6497729B1 (en) 1998-11-20 2002-12-24 The University Of Connecticut Implant coating for control of tissue/implant interactions
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
EP1178791A2 (en) * 1999-05-07 2002-02-13 Johns Hopkins University School of Medicine The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
US6290713B1 (en) * 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
US6317616B1 (en) 1999-09-15 2001-11-13 Neil David Glossop Method and system to facilitate image guided surgery
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6319273B1 (en) 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
ES2311507T3 (en) 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY PHOTODYNAMIC THERAPY FOR TREATMENT OF OPHTHALMIC AFFECTIONS.
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6357568B1 (en) * 2000-09-27 2002-03-19 Shou Mao Chen Structure for protecting a luggage shell
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
CA2429998C (en) * 2000-11-29 2012-01-17 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US6595945B2 (en) 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US20040198829A1 (en) * 2001-04-23 2004-10-07 Sponsel William Eric Prostanoids augment ocular drug penetration
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US6559173B1 (en) 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
EP1430048A1 (en) 2001-09-27 2004-06-23 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
MXPA04009434A (en) * 2002-04-03 2005-01-25 Allergan Inc (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors.
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US6699863B1 (en) 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7915443B2 (en) 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
JP5122460B2 (en) 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド Compositions and methods for intraocular delivery of therapeutic agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions

Also Published As

Publication number Publication date
US7771742B2 (en) 2010-08-10
US8968766B2 (en) 2015-03-03
CA2838526C (en) 2016-11-29
US8404267B2 (en) 2013-03-26
JP5985536B2 (en) 2016-09-06
JP5608138B2 (en) 2014-10-15
JP2011224408A (en) 2011-11-10
JP5586637B2 (en) 2014-09-10
EP1742610B1 (en) 2013-06-12
US20050244477A1 (en) 2005-11-03
WO2005107706A2 (en) 2005-11-17
US20120258163A1 (en) 2012-10-11
AU2005244780B2 (en) 2010-03-25
AU2005244780A1 (en) 2005-12-01
CA2838526A1 (en) 2005-12-01
AU2005240093A1 (en) 2005-11-17
JP2007535556A (en) 2007-12-06
CA2565182C (en) 2014-07-08
US8409607B2 (en) 2013-04-02
US20130330395A1 (en) 2013-12-12
US20130210862A1 (en) 2013-08-15
WO2005107706A3 (en) 2006-01-12
JP5582680B2 (en) 2014-09-03
US20050244470A1 (en) 2005-11-03
US8465778B2 (en) 2013-06-18
US20080260803A1 (en) 2008-10-23
AU2005240093B2 (en) 2011-05-12
US9056045B2 (en) 2015-06-16
US8481069B2 (en) 2013-07-09
EP1750665A1 (en) 2007-02-14
EP1742610A1 (en) 2007-01-17
JP2007535567A (en) 2007-12-06
JP2012067143A (en) 2012-04-05
EP1750665B1 (en) 2012-07-11
WO2005112884A1 (en) 2005-12-01
US20080254096A1 (en) 2008-10-16
BRPI0509461A (en) 2007-09-04
JP2014156496A (en) 2014-08-28

Similar Documents

Publication Publication Date Title
CA2565182A1 (en) Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer
Lee et al. Biodegradable implants for sustained drug release in the eye
Yasukawa et al. Intraocular sustained drug delivery using implantable polymeric devices
JP2018171519A (en) Sustained drug delivery implant
CN105682645B (en) Intraocular implant and its application method containing prostamides
Yasukawa et al. Drug delivery from ocular implants
Cao et al. Recent advances in intraocular sustained-release drug delivery devices
Moshfeghi et al. Micro-and nanoparticulates
AU777727B2 (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CN105073153B (en) Intraocular implant containing prostate amine
CN101890167B (en) The sustained release pharmaceutical composition that can conveniently implant
US10350196B2 (en) Long-acting spiro-isoxazoline formulations
Kearns et al. Drug delivery systems for the eye
WO2007084765A3 (en) Injectable combination therapy for eye disorders
Jervis A summary of recent advances in ocular inserts and implants
US20130071349A1 (en) Biodegradable polymers for lowering intraocular pressure
BRPI0510439A (en) sustained release intraocular implants containing macromolecules and related methods
JP2010536797A5 (en)
RU2749426C2 (en) Non-invasive medicine delivery technique using eye inlay
CA2427655A1 (en) Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization
JP2007535552A5 (en)
AR048646A1 (en) INTRAOCULAR IMPLANT OR BIODEGRADABLE INTRAVITREO THAT INCLUDES A THYROSINE KINASE INHIBITOR AND A BIODEGRADABLE POLYMER, METHOD TO PRODUCE IT AND CORRESPONDING MEDICATION
WO2009137085A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP2008540552A5 (en)
BRPI0708622A2 (en) eye therapy using sirtuin activating agents

Legal Events

Date Code Title Description
EEER Examination request